Skip to main content
. 2014 Mar 10;123(22):3406–3413. doi: 10.1182/blood-2013-11-538546

Table 2.

Patient disposition

Disposition Primary study (N = 64) Extension study (N = 19)
Idelalisib dose regimen, n (%)
 50 mg BID 7 (11) 0
 150 mg QD 9 (14) 3
 150 mg BID (3 wk on, 1 wk off) 12 (19) 1
 100 mg BID 7 (11) 3
 300 mg QD 5 (8) 3
 150 mg BID 10 (15) 3
 200 mg BID 10 (15) 4
 350 mg BID 4 (6) 2
Completed study (≥48 wk), n (%) 19 (30) 1 ongoing
Discontinued, n (%) 45 (70) 18 (95)
 Disease progression 23 (36) 9 (47)
 AE 8 (13) 4 (21)
 Patient/investigator request 2 (3) 2 (11)
 Withdrew consent 2 (3) 0
 Prohibited drug 1 (2) 0
 Patient noncompliance 1 (2) 0
 Death 0 1 (5)
 Other* 8 (13) 2 (11)
*

Other in primary study includes: investigator decision/mild progression, need of additional therapy, deterioration of functional status, limited benefit; poor tolerance, patient decision/head injury; difficulty with transportation, and incarceration.